title: SEOM guidelines: non-seminomatous germ cell cancer (NSGCC).
abstract: Non-seminomatous germ cell cancer (NSGCC) is a curable disease; its treatment has not essentially changed since the 1980s. BEP (bleomycin, etoposide, cisplatin) chemotherapy remains the standard of care. NSGCC's management can be summarised by three trees of decision, which contemplate staging, treatment with chemotherapy and management of postchemotherapy residual disease. The role of high-dose chemotherapy remains to be established. TIP (paclitaxel, iposfamide, cisplatin) chemotherapy is still the standard salvage treatment for patients progressing after BEP chemotherapy. Surgical removal of any residual disease is mandatory. For patients with poor prognosis, consultation with a centre of expertise is strongly recommended.
authors.affiliation: Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. baldomir@yahoo.com
authors.forename: Pablo
authors.initials: P
authors.lastname: Maroto
authors.forename: Xavier
authors.initials: X
authors.lastname: Garcí Del Muro
authors.forename: Javier
authors.initials: J
authors.lastname: Sastre
authors.forename: Dolores
authors.initials: D
authors.lastname: Isla
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D018239:Seminoma / Q000175:diagnosis / Q000628:therapy; D012955:Societies, Medical; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents